Richard Sachse

Richard Sachse holds a degree in medicine from the Friedrich-Alexander-University Erlangen, Germany and a board certification in Clinical Pharmacology. With more than 25 years of experience as a physician and scientist, he has extensive expertise in pharmaceutical development covering the entire value chain from preclinical to registration. In addition to registration studies, he is especially experienced in the design and implementation of translational programs to bridge research programs to the clinic.

Prior to joining SOTIO, Richard led the medical, scientific, regulatory and pharmacovigilance activities as Chief Scientific Officer at Neovii. As Chief Scientific Officer/ Chief Medical Officer at Aeterna Zentaris, he was successful in achieving FDA approval of Macimorelin. This was preceded by steady growth through several managerial career steps at Bayer, Peptor, Schwarz Pharma, UCB and Boehringer Ingelheim. He began his medical and scientific career as a Postdoctoral Fellow at the National Cancer Center Research Institute, Tokyo, Japan and later as a Resident in Internal Medicine at the University Erlangen, Germany.